SLC5A2 and type 2 diabetes mellitus: A recent meta-analysis by Dimitriadis et al (2024)[54] also revealed that long-term use of SGLT2 inhibitors clearly reduced the risk of CIN in patients with type 2 diabetes undergoing PCI.